



公告日期	2026/10/8
異動類別	新進藥品
異動原因	藥委會決議
異動描述	Ravulizumab inj 300mg/3mL/vial (Ultomiris®)妥立瑞自即日起可開方使用。

異動內容	
料號	783853
學名	Ravulizumab
商品名	Ultomiris
中文名	妥立瑞
主成份及含量	300mg/3mL/vial
製造廠名稱	Alexion Pharma International Operations Limited (Alexion)
產地	愛爾蘭
健保代碼	YC00045216
外觀/圖檔	
用法	靜脈滴注
小孩劑量	Atypical hemolytic uremic syndrome (aHUS), Paroxysmal nocturnal hemoglobinuria (PNH): <u>Infants, Children, and Adolescents:</u> 5-10 kg: IV: 600 mg as a loading dose, followed by 300 mg Q4W starting 2 weeks after the loading dose. 10-20 kg: IV: 600 mg as a loading dose, followed by 600 mg Q4W starting 2 weeks after the loading dose. 20-30 kg: IV: 900 mg as a loading dose, followed by 2100 mg Q8W starting 2 weeks after the loading dose. 30-40 kg: IV: 1200 mg as a loading dose, followed by 2700 mg Q8W starting 2 weeks after the loading dose. <u>Other condition refer to adult dosing.</u>

成人劑量	Atypical hemolytic uremic syndrome (aHUS), Paroxysmal nocturnal hemoglobinuria (PNH): 20-30 kg: IV: 900 mg as a loading dose, followed by 2100 mg Q8W starting 2 weeks after the loading dose. 30-40 kg: IV: 1200 mg as a loading dose, followed by 2700 mg Q8W starting 2 weeks after the loading dose. aHUS, PNH, Neuromyelitis optica spectrum disorder (NMOSD): 40-60 kg: IV: 2400 mg as a loading dose, followed by 3000 mg Q8W starting 2 weeks after the loading dose. 60-100 kg: IV: 2700 mg as a loading dose, followed by 3300 mg Q8W starting 2 weeks after the loading dose. ?100 kg: IV: 3000 mg as a loading dose, followed by 3600 mg Q8W starting 2 weeks after the loading dose.
副作用	